arthritis Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy controls: negative for IgM-RF and anti-CCP antibodies Autoantibody-positive individuals: positive for IgM-RF and/or anti-CCP antibodies + either arthralgia or a first degree relative with RA. Early arthritis patients: arthritis
Exclusion criteria
Exclusion criteria: For all individuals: - Current/previous use of disease modifying anti-rheumatic drugs (DMARDs). - If applicable: patients in whom anticoagulant therapy cannot be temporarily stopped before the procedure - Systemic prednisolone use less then 28 days before enrolment - Present or previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19) - Presence of any disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolone for COPD). - History of chronic viral infection - History of autoimmune diseases - History of malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Differences in phenotype of B-/T-cells/dendritic cells and gene expression in: - autoantibody-positive individuals who do/do not develop RA - autoantibody-positive individuals in comparison to autoantibody-negative healthy controls - autoantibody-positive individuals in comparison to early RA/UA patients | — |
Secondary
| Measure | Time frame |
|---|---|
| 2) antigen specificity of these involved immune cells. 3) involvement of the stromal microenvironment of the lymph nodes in the development of RA. | — |
Countries
Netherlands
Outcome results
None listed